Wedbush Adjusts Price Target on Geron to $5 From $6

After Geron announced it would discontinue its Phase 3 IMpactMF trial, Wedbush lowered its price target to $5 from $6 while maintaining an Outperform rating. The firm said Geron’s core RYTELO business remains on track.